THRX Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 46.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Theseus Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Theseus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Theseus Pharmaceuticals Share Price & Price History

Current Price: $4.06
Price Change: +0.30 (1.20%)
As of 02/14/2024 01:00 AM ET

This chart shows the closing price history over time for THRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Theseus Pharmaceuticals Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Theseus Pharmaceuticals (NASDAQ:THRX)

91.05% of Theseus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at THRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$10M$0$10MTotal InflowsTotal Outflows
Theseus Pharmaceuticals logo
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Read More on Theseus Pharmaceuticals

Today's Range

Now: $4.06
Low: $4.06
High: $4.06

50 Day Range

MA: $4.06
Low: $4.06
High: $4.07

52 Week Range

Now: $4.06
Low: $2.05
High: $12.37

Volume

N/A

Average Volume

592,167 shs

Market Capitalization

$179.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.98

Who are the company insiders with the largest holdings of Theseus Pharmaceuticals?

Theseus Pharmaceuticals' top insider shareholders include:
  1. Carl L Gordon (Director)
  2. Foresite Capital Management V, (Major Shareholder)
Learn More about top insider investors at Theseus Pharmaceuticals.